Toxin Exposure and Immune Dysregulation in Non-Hodgkin Lymphoma
Part of paid clinical trials in Bethesda, Maryland.
- Sponsor
- Henry M. Jackson Foundation for the Advancement of Military Medicine
- Study ID
- NCT07652580
- Status
- Recruiting
Conditions
- B-cell Lymphoma
- Immune Dysregulation
- Lymphoma Non-Hodgkin
- Non-Hodgkin Lymphoma
Eligibility Criteria
- Sex
- ALL
- Age
- 4 Years - N/A
- Healthy Volunteers
- Not accepted
Study Details
The goal of this observational cohort study is to learn how toxin and occupational exposures, germline genetic variation, and immune dysregulation relate to B-cell non-Hodgkin lymphoma among active-duty service members and other Military Health System beneficiaries. The main questions are whether specific exposures and germline variants are associated with B-cell NHL subtype, immune dysfunction, and clinical outcomes. Participants will complete exposure and medical-history surveys, provide biospecimens for immune and genomic testing, and may be followed annually for up to 3 years.
Key Dates
- Start date
- May 1, 2025
- Status verified
- Jun 2026
- Primary completion
- May 1, 2028
- Completion
- May 1, 2028
Study Design
- Enrollment
- 300 participants (estimated)
Arms
- Arm: Cohort 1Active duty service members (ADSMs) and other Military Health System (MHS) beneficiaries who have a history of B-cell non-Hodgkin Lymphoma (NHL) and have achieved clinical remission.
- Arm: Cohort 2ADSMs and other MHS beneficiaries ages 18 and older who are newly diagnosed with B-cell NHL and/or are not undergoing active treatment.
- Arm: Cohort 3Other MHS beneficiaries ages 4-17 who are diagnosed with B-cell NHL and are treatment naive.
Primary Outcome Measure
Aim 1: Characterize occupational exposures and their impact on health outcomes and immune health of ADSMs and other MHS beneficiaries with B-cell NHL. [ Time Frame: 3 years ]
Central Contacts
- Christin B. Destefano, MD, Lt Col, MC, USAF(301) 295-3190
- W. Grant Day, MD, LCDR, MC, USN(757) 953-2194
Locations (3)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Uniformed Services University of the Health Sciences | Bethesda | Maryland | 20814 | - |
| Walter Reed National Military Medical Center | Bethesda | Maryland | 20814 | Jeremy Perkins, MD, FACP, COL, US Army (ret) (PRINCIPAL_INVESTIGATOR) |
| Naval Medical Center Portsmouth | Portsmouth | Virginia | 23708 | - |
Find similar trials in Bethesda, MD
Related Studies
- A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)Recruiting · Center for International Blood and Marrow Transplant Research · Birmingham, Alabama
- Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed/Refractory B-cell LymphomaPHASE1/PHASE2 · Recruiting · National Cancer Institute (NCI) · Bethesda, Maryland
- Dose-escalation and Dose-expansion Study of Safety of Azer-cel (PBCAR0191) in Participants With Relapsed/Refractory (r/r) Non-Hodgkin Lymphoma (NHL) and r/r B-cell Acute Lymphoblastic Leukemia (B-ALL)PHASE1 · Recruiting · Imugene Limited · Gilbert, Arizona
- A Dose-Escalation and Expansion Study of BGB-16673 in Participants With B-Cell MalignanciesPHASE1/PHASE2 · Recruiting · BeOne Medicines · Birmingham, Alabama